Jeremy Skillington of Poolbeg Pharma discusses their Nasdaq partnership for development of an optimised oral drug to treat a metabolic condition

Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses their partnership with Nasdaq-Listed Biopharma company for the development of an optimised oral drug to treat a metabolic condition. Under the agreement, the Company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg's licensed oral delivery technology.